Eli Lilly’s (NYSE:LLY) released study results on Monday that showed the long-term efficacy of mirikizumab, marketed under the brand name Omvoh, against both ulcerative colitis (UC) and Crohn's ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979. You are breastfeeding or plan to breastfeed. It is not known if ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

Eli Lilly’s Omvoh (mirikizumab) has been recommended by the European Medicines Agency’s human medicines committee to treat Crohn’s disease. The Committee for Medicinal Products for Human Use (CHMP) ...

Eli Lilly said it received Food and Drug Administration ... The treatment, developed by the pharmaceutical company under the brand name Omvoh, is now approved to treat two types of inflammatory ...

Eli Lilly announced last year its medication Omvoh was approved by the Food and Drug Administration for treating adults with moderate-to-severe ulcerative colitis. Morphic has been developing its ...

Jaypirca and Omvoh should also contribute meaningfully through the end of the decade. In other words, Eli Lilly's revenue should continue growing at a good clip. The midpoint of the company's ...